Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.

Life sciences - 1 Mar 2020

Liao Siyan, Floyd Cecilia, Verratti Nicholas, Leung Lauren, Wu Chun

Abstract excerpt

AIMS: Vismodegib is an effective antagonist of smoothened receptors for treatment of locally advanced or metastatic basal cell carcinoma. However, it often suffers from drug resistance due to mutations. Two common mutants, D4736.55G and W5357.55L, were found to cause serious drug resistance. Although the reduction of drug binding affinity (~40-fold) was thought to be the major reasons, the detailed structural,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Carcinoma, Basal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Protein Domains

Share to Pyridines

Share to Smoothened Receptor

Source

Identifiers

PMID: 31953165
DOI: 10.1016/j.lfs.2020.117302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations.PMID 31953165Read ↗

Molecular modeling study on resistance of WT/D473H SMO to antagonists LDE-225 and LEQ-506.Semantic proximity Read ↗

Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.Semantic proximity Read ↗

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinomaSemantic proximity Read ↗

Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant.Semantic proximity Read ↗

Smoothened variants explain the majority of drug resistance in basal cell carcinoma.Semantic proximity Read ↗

Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.Semantic proximity Read ↗

Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened.Semantic proximity Read ↗

Impacts of Mutations in the P-Loop on Conformational Alterations of KRAS Investigated with Gaussian Accelerated Molecular Dynamics Simulations.Semantic proximity Read ↗

Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.Semantic proximity Read ↗

Targeting the hedgehog pathway to treat basal cell carcinoma.Semantic proximity Read ↗

A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.Semantic proximity Read ↗

Rare deleterious mutations in Bruton's tyrosine kinase as biomarkers for ibrutinib-based therapy: an in silico insight.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.